Key facts
- It has raised $29.4M; the latest was Later Stage VC in Aug 2025.
- Notable investors include GSR Ventures China, CCB International, Zhongguancun Science City, Beijing Zhongguancun Collaborative Innovation Investment Fund Management, GoldenSand Capital — 11 tracked in total.
- Status: Privately Held (backing).
Investors
11+- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for FireGen Biomedicals
- ·The full record, as it builds
Funding rounds
No funding rounds for FireGen Biomedicals are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About FireGen Biomedicals
Provider of cancer screening services intended for oncology treatment. The company primarily focuses on the development of genetic tumor screening, early screening, and targeted drug product development, as well as medical technology services. It mainly provides early cancer screening, tumor drug guidance, and tumor genetic risk assessment, offering innovative cancer screening solutions to patients.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2016
- Website
- fgbiomed.com/
- Ownership
- Privately Held (backing)
FireGen Biomedicals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in FireGen Biomedicals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on FireGen Biomedicals in its N-PORT filings yet. We sweep new filings monthly.